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Summary Dose intensity may be an important deterrminant of the outcome in cancer chemotherapy. but is
often limited by cumulative haematological toxicity. The availability of haematopoietic growth factors such as
granulocyte colony-stimulating factor (G-CSF) and of peripheral blood progenitor cell (PBPC) transplantation
has allowed the development of a new treatment strategy in which several courses of high-dose combination
chemotherapy are administered for the treatment of solid tumours. PBPCs were mobilised before
chemotherapy using 12 or 30 Ljg kg day' G-CSF (Filgrastim) for 10 days, and were collected by 2-5
leucaphereses. The yields of mononuclear cells, colony-forming units and CD34-positive cells were similar at
the two dose levels of Filgrastim, and the numbers of PBPCs were sufficient for rescue following multiple
cycles of chemotherapy. High-dose chemotherapy (cyclophosphamide 2.5 g m-2 for 2 days, etoposide
300 mg m- for 3 days and cisplatin 50 mg m2 for 3 days) was administered sequentially for a median of
three cycles (range 1-4) to ten patients. Following the 30 evaluable cycles, the median duration of leucopenia
S 0.5 x 1091-1 and < 1.0 x 10 I`l was 7 and 8 days respectively. The median time of thrombopenia
S 20 x 109 1' was 6 days. There was no cumulative haematological toxicity. The duration of leucopenia, but
not of thrombopenia, was inversely related to the number of reinfused CFU-GM (granulocyte-macrophage
colony-forming units). In the majority of patients, neurotoxicity and ototoxicity became dose limiting after
three cycles of therapy. However, the average dose intensity delivered was about three times higher than in a
standard regimen. The complete response rate in patients with small-cell lung cancers was 66% (95% CI
30-92%) and the median progression-free survival and overall survival were 13 months and 17 months
respectively. These results are encouraging and should be compared, in a randomised fashion, with standard
dose chemotherapy.
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Small-cell lung cancer (SCLC) has been shown to be sensitive
to a variety of single agents and combination chemotherapy,
but the early emergence of resistant tumour cells remains the
main cause of treatment failure. The effect of dose on tumour
response is well established (Antman and Souhami, 1993),
even if the impact on survival is unclear. There are sugges-
tions that the initial administration of high doses of
chemotherapy improves disease-free and overall survival in
patients with limited disease (Arriagada et al., 1993). It
emphasises the importance of initial intensity in overcoming
the development of resistant tumour cells. In experimental
models, repeated cycles of chemotherapy have been shown,
to be more cytotoxic than a single one (Teicher et al., 1989).
Based on these data, we attempted to develop an intensive
regimen of combination chemotherapy that could be
administered over multiple sequential cycles in unpretreated
patients and to obtain a 3- to 4-fold intensification of
chemotherapy compared with a standard regimen.
The chemotherapy regimen consisted of a combination of
cyclophosphamide, etoposide and cisplatin. These agents
were selected because of their dose-response in SCLC and
their synergism in animal models (Johnson et al., 1987). For
each agent, a dose intensity which is known to produce only
minimal non-haematological toxicity was chosen.
Haematological toxicity was expected, but in order to reduce
its duration and to avoid a cumulative exhaustion of
haematopoiesis, peripheral blood progenitor cell (PBPC)
transplantation and granulocyte colony-stimulating factor
(Filgrastim) were used as haematological support. We plan-
to give four cycles of intensive combination chemotherapy,
and according to dose intensity calculations (Hryniuk, 1988)
the average relative dose intensity of our regimen was pro-
jected to be four times higher than a standard regimen
administered for six cycles (Cortes Funes et al., 1982). The
feasibility of such an approach was the aim of our study.
Patients and methods
Between June 1992 and January 1994, ten patients enrolled
on the study. To be eligible, patients had to have normal
cardiac, hepatic and renal functions, a performance status
<2 according to ECOG (Oken et al., 1982), to have given
informed consent and to be <65 years old. Patients who
had received chemotherapy or colony-stimulating factors in
the preceding 12 months were excluded. The study was
designed to include patients with a biopsy-proven SCLC, but
one 30-year-old woman with metastatic breast cancer to the
lung was also entered to test the feasibility of the prog-
ramme. Acute toxicity was recorded according to the World
Health Organization (1979) criteria. Limited disease was
defined as that confined to one hemithorax, mediastinum and
supraclavicular nodes, provided all volumes could be
included in the same radiaotherapy field as the primary
tumour. The presence of ipsilateral pleural effusion was
classified as limited disease. All the other conditions were
considered as extensive disease (Stahel et al., 1989). Response
was evaluated 4 weeks after the end of the high-dose
chemotherapy regimen, by means of standard radiography,
CT scan and bronchoscopy with biopsy. A complete response
was defined as the complete disappearance of all clinical,
radiological and, when applicable, pathological evidence of
disease for a period of 4 weeks. Partial response was any
response less than complete but with a greater than 50%
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reduction in the sum of products of the cros-diameter of all
measurable lesions. The study was approved by the ethical
committee at our institution.
Mobilisation and collection ofperipheral bloodprogenitor cells
Mobilisation of PBPCs was performed before chemotherapy
using Filgrastim administered subcutaneously over 10 days at
12 pigkg' day-' (seven patients) and 30 pgkg-g day-'
(three patients). Starting on day 5, leucapheresis was per-
formed a maximum of five times. In three patients, the
harvesting procedure was carried out using a blood separator
V-SO intermittent flow device (Haemonetics, Braintree, MA,
USA) and in seven patients using a CS-3000 continuous flow
device (FenwaL Deerfield, IL, USA). The end points for each
collction were either 4 h (Haemonetics) or 81 of blood
(Fenwal). Dimethylsulphoxide (DMSO 10% final concentra-
tion) was added to fractions containing mononuclear cells.
The samples were frozen using a controlled rate freezer and
stored in liquid nitrogen until use. CFU-GM
(granulocyte-macrophage colony-forming units) were cul-
tured using a double-layer semisolid agar technique as
previously described (Pike and Robinson, 1970). Cells expres-
sing the surface membrane CD34 antigen were identified with
murine monoclonal antibodies QBEND1O (Immunotech,
Marseile, France) or 4PCA2 (clone 8G12; Becton Dickinson,
San Jose, CA, USA). At the time of reinfusion, PBPCs from
one or two pheresis collections were rapidly thawed at 37C
and each admid over 10-20 min. A back-up bone
marrow harvest was performed in the first four patents, but
was never used.
Treatment regimen
The treatment programme consisted of cyclophosphamide
2.5 g m-2 on days 1 and 2, etoposide 300 mg m-2 on days 1,
2 and 3 and cisplatin 50 mg m-2 on days 1, 2 and 3 and was
planned to be repeated every 21 days for a total of four
cycles. Mesna 4.0 gm-2 day-' was given as a continuous
intravenous infusion on days 1 and 2, starting 1 h before
cyclophosphamide. Hydration consisted of41 of 5% dextrose
or normal saline supplemented with potassium chloride or
magnesium sulphate. Frusemide 20 mg i.v. was given to
maintain a urine output of - 200 ml h-'. Prophylactic
antiemetic therapy consisted of onanstron or ganisetron
with high-dose methylprednisolone. Lorazepam and metoc-
lopramide were added if necessary. Ciprofloxacin and
phenoxymethylpenilin were given during the periods of
neutropenia and broad-spectrum antibiotics were
administered during febrile episodes. Platelet transfusions
were inistered for platelets counts lower than 10 x 1091-1
or in case of haemorrhagic events. PBPCs were reinfused
24-48 h after the end of chemotherapy, followed by Filgras-
tim at 12 jg kg-' day-' or 30 jg kg-' day-' subcutaneously
for 14 days or less in case of early recovery. Complete
responders received 45 Gy radiotherapy at the primary
tumour site and the mediastinum on completion of the treat-
ment programme.
Statistics
Comparison between the groups was done usng the Kol-
mogorov-Smirnov test (Siegel, 1956). Analysis of disease-
free survival or overall survival was done using the Kap-
lan-Meier method (Kaplan and Meier, 1958). Dose inteIsity
(DI) was calculated according to Hryniuk (1988) and Longo
et at., (1991).
The patients had a median age of 50 years (range 30-62) and
their median performance status was 1 (range 0-1). Except
for the 30-year-old woman with metastatic breast cancer, five
patients had limited (stage lIIa, two patients; stage IUb,
three patients) and four extensive SCLC. One patient with a
severe superior vena cava syndrome received radiotherapy on
the mediastinum (20 Gy) after PBPC collction, but before
chemotherapy. One patient with SCLC had had a mastec-
tomy for breast cancer 5 years previously and then received
adjuvant chemotherapy and radiotherapy, as did the patient
with breast cancer. Because of internal mammary and right
supraclavicular lymph node recurrence, this last patient also
had radiotherapy to the mediastinum 1 month before starting
on the programme.
Thirty cycles were evaluable. Three patients completed
four cycls, five received only three cycles and one patient
had two cycles and another one cycle. The reason for not
completing the four cycles was, in five patients, the severe
non-haematological toxicity which was observed in the first
three patients. One patient withdrew after two cycles and one
after one cycle because ofcomplications due to superior vena
cava syndrome.
PBPC mobiisation and collection
After 5 days of Filgrastim, at the start of leucaphereses, the
median leucocyte count was 67.7 x 1091-' (range 30.4-79.2).
Following a median of four leucaphereses (range 2-5), the
collections yielded medians of mononuclear cells, CFU-GM
and CD34-positive cells of 12.9 x 10 kg-' (range 4.2-20.8),
40.2 x 104kg-' (range 4.2-214.8) and 7.5 x 10' kg-' (range
1.6-21.9) respectively and were not affected by the dose of
Filgrastim.
Toxicity
The durations of leucopenia and thrombopenia were cal-
culated from the day of PBPC reinfusion to recovery and as
the number of days with low leucocyte or thrombocyte
counts. The overall median time to leucocyte counts >0.5
and l.0x 109'-' was 9 (range 8-14) and 10 days (range
8-15) respectively. The median duration with a leucocyte
count <0.5 and < 1.0 x 109I' - was 7 days (range 5-12) and
8 days (range 6-13). As seen in Figure la, there was no
cumulative neutropenia-
The median time to leucocyte count > 1.0 x 109 1` for the
first, second, third and fourth cycles of treatment was 10, 9,
10.5 and 10 days respectively. The median time to
> 1.0 x 10 1-' lucocytes with either dose of Flgrastim was
10 days. Recovery from thrombocytopenia is demonstrated
in Figure lb with a median time to > 20 x 10 -I of 11 days
(range 9-15), without any cumulative thrombopenia.
The median number ofCFU-GM kg-' reinfused after each
cycle of chemothebay was 8.32 x 104kg-' (range
1.69-61.0). There ias direct relationship between the
number ofreinfused CFU.J'M and recovery of marrow func-
tion. Wben the number of CFU-GM kg-' was
,I0 x I04kg-', the median time to a leucocyte count of
1.0 x101-l was 11 days (range 9-15). It was 9 days
(range 8-10) with a CFU-GM count of > I0 x 0I kg-'.
This difference was highly significnt (P = 0.001). The
number of CFU-GM kg-' transfused had no influence on
platelet recovery >20 x 10' 1-'. After the administation of
>10 or <10X0 0 x kg-' CFU-GM, median duration of
platelet recovery was 10.5 days (range 9-14) and 12 days
(range 9-15) respctively (P>0.1).
Proven infection developed during 37% of 30 cycles of
treatments, with no correlation with Filgrastim dosage. There
was also no correlation with the number of days on int-
ravenous antibiotcs, the length of stay in hospital and
number of platelet or red cell transfusions. Duration of
hospitalisation was the same during the first and subsequent
cycles with a median of 18 days (range 15-44). The longest
period of hospitalisation was observed in the patient with
superior vena cava syndrome, who experienced severe
oesophagitis and bacteraemia, possibly related to previous
radiotherapy.
Neurotoxicity and ototoxicity were severe in the three
patients who received four cycles of treatment, and this led
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Tak I Non-haematological toxicity (WHO grading)
Cycle nmber
nII III IV
Peripheral neuropathy 0 0 1 3
Median (range) (0-1) (0-2) (2-3)
Hearing 0 0 0 2
Median (range) (0-1) (0-2) (0-2)
Nausea/vomiting 2 2 2 2
Median (range) (1-3) (0-3) (1-3) (1-2)
Mucosatis 0 0 0 0
Median (range) (0-1) (0-1) (0-3)
Diarrhoea 1 1 1
Median (range) (0-2) (0-4 (0-2)
Weightloss 1 1 2 2
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FVIe 1 (a) Median kucocyte count according to cycles. (b)
median platelet count according to cyces.
us to cancel the administration of the fourth cycle in subse-
quent patients. The non-haematological toxicities are
reported in Table I. Peripheral neuropathy WHO grade I
oured in two patients, grade 2 in four patients and grade 3
in one patient receiving two, three and four cycles of treat-
ment respectively. Timnitus occurred in three patients after
one cycle of treatment. After three cycles of treatment, one
patient developed moderate hearing loss, which also
developed in the three patients receivimg four cycls of treat-
ment. Gastrointetinal toxicity, consisting of nausea and
vomiting and mucositis and diarrhoea, was not dose-limiting.
Only one patient had rectorrhagia following a transient ileus.
Weight loss > 10% of the body mass occurred in three
patients after two cycles, in five patients after three cycles
and in all three patients after four cycles of treatment. All
patients complained of fatigue, which imposed treatment
delays in the majority of them.
Dose intensity
Intensification of chemotherapy can be measured in three
different ways: as dose per unit of time, as single dose
intensity or as total dose delivery. Calculations and com-
parisons can be made based on planned treatment or on the
actual delivered chemotherapy. We compared the planned
doses of our regimen with a standard one which the same
three drugs were used (Cort6s Funes et al., 1982). The single
dose intensity and the total dose of cyclophosphamide were
8.3 and 5.5 times hgher respectively, and of eoposide three
and two times higher, and of dsplatin 1.9 and 1.25 times
higher than the standard regimen. The planned average dose
intensity per unit of time was increased 4.4-fold. However,
owing to treatment delays and missing cycles, the actual
delivered chemotherapy was a median of 1017
mgm2 week'- (range 416-1360) of cyclophosphamide ins-
tead of the planned 1666 mgm-2week'-. It was 184
mgm-2week-' (range 75-267) of etoposide instead of 300
mgm- week-' and 31 mgm-2week-' (range 13-33) of
cisplatin instead of 50 mgm2-week-'. The actual average
percentage of dose intensity for all three drugs was 61p% of
the planned dose intensity. Even if data on actual dose
delivery of the standard regimen are not available, we
estimate that the escaktion in dose intensity of our regimen
was about 3-fold.
Anti-twuour activity
Response evaluation was not the primary aim of this study.
The patient with breast cancer and lung metastases developed
a complete clinical remission, lasting 24 + months. Among
the nine patients with SCLC, six were complete responders
confirmed by bronchoscopy and three partial responders.
With a median follow-up period of 20 months, progression
was detected in six of the nine responding patients; of these,
four had recurrences at the primary site and four had distant
metastases (pleura two patients; liver, three patients; and
brain, two patients). The median progresson-free survival
and overall survival were 13 and 17 months respectively.
Dis_ m`
High-dose chemotherapy has commonly been administered as
a single cycle of high peak intensity and resulted in higher
cure rates in patients with acute lukaemia or lymphoma and
encouragng results in some solid tumours (Antman and
Souhmi 1993). To improve the magment of SCLC, it is
nyssary to develop a treatment capable ofcircumventing or
minimising the impact of drug resistance. The intsification
of chemotherapy appears to be a potentially effectiv treat-
ment strategy. However, the majority of the studies fued
on single dose intensity instead of total dose or dose rate
intensity. For long-term remissions and cure of
chemotherapy-sensitive malignancie, multiple cyles of stan-
dard combination chemotherapy are required. The same may
be true for high-dose chemotherapy in the treatment of kss
responsive solid tumours. The availability of baematopoietic
growth factors and peripheral blood progenitor cells allowed
us to consider the possibility of developing a treatment
approach in which repeated courses of high-dose combina-
tion chemotherapy were adnlmstered sequentially over four
cycles with an increased projected average dose intensity of
more than four times that of a standa regimen. However,
the non-haatological toxicity due to cisplatin became the
dose-limiting toxiticy (Leyvraz et al., 1993). All patients
receiving four cycles of therapy experienced severe neuro-
and ototoxicity which prevented the adminitation of the
fourth cycle in subsequent patients. Altogether, missng
cycles and treatment delays led to the chemotherapy actually
delivered being 61% of the planed dose intensity. This
remained, nevertheless, about three times the intensity of a
standard regimen. In comparison, the increase in dose inten-
sity of accelerated weekly schedules is only 1.5 times that of
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and the addition of G-CSF does not significantly affect fur-
ther intensification (Miles et al., 1994).
The collection of PBPCs before chemotherapy allowed
easy planning of the sequential intensive treatment. In the
few reports of multiple cycles of high-dose chemotherapy, the
PBPCs were collected at the end of each cycle of
chemotherapy at the time of mononuclear cell and platelet
recovery, making the timing of leucapheresis less predictable
(Crown et al., 1992; Tepler et al., 1993) and possibly exhaus-
ting the ability to mobilise PBPCs and the capacity of stem
cells to reconstitute marrow functions (Shea et al., 1994). The
optimum method for mobilisation of PBPCs is still open to
question, even if there are suggestions that chemotherapy,
followed by colony-stimulating factors, induces a higher yield
than any agent alone (Teshima et al., 1993).
Filgrastim was administered after the reinfusion of PBPCs.
When PBPCs or haematopoietic growth factors are used
alone after high-dose chemotherapy, haematological recovery
time is prolonged compared with the administration of both
modalities (Kritz et al., 1992; Shimazaki et al., 1993; van der
Wall et al., 1994). The dose of Filgrastim did not affect the
rate of leucocyte or platelet recovery or modify the incidence
of infections, the number of days on antibiotics or the dura-
tion of hospitalisation. Low-dose Filgrastim might be as
effective. Indeed, in a randomised trial, even though the dose
of 20 ligkg-' day-' G-CSF was marginally more effective
than 5 or 10 ;Lg kg-' day'- following bone marrow trans-
plantation, the dose of 5 g kg-' day-' was recommended
for further trials (Linch et al., 1993).
The anti-tumour activity of our regimen was substantial,
with a 66% complete response rate (95% CI 30-92%). which
is similar to other intensive treatment strategies (Souhami et
al., 1985; Johnson et al.. 1987). It resulted in a median
progression-free survival of 13 months and an overall sur-
vival of 17 months, possibly because of the selection of
patients with good physical condition. However, these results
are encouraging and in the range of the best reported results
for the treatment of patients with limited disease (Elias et al.,
1993).
Further improvements in the design of intensive treatment
strategies may be possible. Radiotherapy might have a role in
controlling bulky or localised disease and should be integ-
rated without compromising the delivery of chemotherapy.
Other combinations of chemotherapeutic agents might be
more suitable for sequential intensive treatment. The
intensification of our regimen was mainly due to the ability
to increase the dose intensity of cyclophosphamide eight
times and that of etoposide 1.8 times. Cisplatin dosage could
not be increased significantly and was the cause of limiting
toxicity. A combination of alkylating agents or the use of
anthracyclines may be more appropriate (Murray, 1987). We
are currently testing the sequential administration of multiple
cycles of high-dose ICE (ifosfamide-carboplatin-etoposide),
which will be evaluated in a randomised fashion against
conventional dose therapy.
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